Related references
Note: Only part of the references are listed.Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Tracking progesterone receptor-mediated actions in breast cancer
Todd P. Knutson et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4
D. M. Cittelly et al.
ONCOGENE (2013)
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight
Cathrin Brisken
NATURE REVIEWS CANCER (2013)
Progesterone regulation of stem and progenitor cells in normal and malignant breast
Sunshine Daddario Axlund et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Apigenin Induces Apoptosis and Blocks Growth of Medroxyprogesterone Acetate-Dependent BT-474 Xenograft Tumors
Benford Mafuvadze et al.
HORMONES & CANCER (2012)
Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009
Sandra A. Tsai et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2011)
Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice
Yayun Liang et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2010)
Apigenin blocks induction of vascular endothelial growth factor mRNA and protein in progestin-treated human breast cancer cells
Benford Mafuvadze et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2010)
Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Rowan T. Chlebowski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: A hypothesis
Kathryn B. Horwitz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Anti-carcinogenic Effects of the Flavonoid Luteolin
Guenter Seelinger et al.
MOLECULES (2008)
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
Christophe Ginestier et al.
CELL STEM CELL (2007)
Progestin-dependent progression of human breast tumor xenografts: A novel model for evaluating antitumor therapeutics
Yayun Liang et al.
CANCER RESEARCH (2007)
Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones
Yayun Liang et al.
ENDOCRINE-RELATED CANCER (2006)
Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: Paracrine and autocrine effects
YY Liang et al.
ENDOCRINOLOGY (2005)
Mammary stem cells, self-renewal pathways, and carcinogenesis
SL Liu et al.
BREAST CANCER RESEARCH (2005)
Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: Preferential regulation by progesterone receptor B
JB Wu et al.
CANCER RESEARCH (2004)
Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity
E Bagli et al.
CANCER RESEARCH (2004)
Breast cancer and hormone-replacement therapy in the Million Women Study
E Banks et al.
LANCET (2003)
Influence of estrogen plus progestin on breast, cancer and mammography in healthy postmenopausal women - The Women's Health Initiative Randomized trial
RT Chlebowski et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Prospective identification of tumorigenic breast cancer cells
M Al-Hajj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial
JE Rossouw et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
RK Ross et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
